Although an inherent low number of IGF-IR molecules per cancer cell may cause primary resistance to anti-IGF-IR antibodies or small molecule inhibitors, this factor appears to be more relevant to inducing secondary resistance when anti-IGF-IR antibodies are used. This evidence concerns the gene IGF1R and cancer.